Jump to: navigation, search
This image is provided by the National Library of Medicine.

WikiDoc Resources for Apramycin


Most recent articles on Apramycin

Most cited articles on Apramycin

Review articles on Apramycin

Articles on Apramycin in N Eng J Med, Lancet, BMJ


Powerpoint slides on Apramycin

Images of Apramycin

Photos of Apramycin

Podcasts & MP3s on Apramycin

Videos on Apramycin

Evidence Based Medicine

Cochrane Collaboration on Apramycin

Bandolier on Apramycin

TRIP on Apramycin

Clinical Trials

Ongoing Trials on Apramycin at Clinical Trials.gov

Trial results on Apramycin

Clinical Trials on Apramycin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Apramycin

NICE Guidance on Apramycin


FDA on Apramycin

CDC on Apramycin


Books on Apramycin


Apramycin in the news

Be alerted to news on Apramycin

News trends on Apramycin


Blogs on Apramycin


Definitions of Apramycin

Patient Resources / Community

Patient resources on Apramycin

Discussion groups on Apramycin

Patient Handouts on Apramycin

Directions to Hospitals Treating Apramycin

Risk calculators and risk factors for Apramycin

Healthcare Provider Resources

Symptoms of Apramycin

Causes & Risk Factors for Apramycin

Diagnostic studies for Apramycin

Treatment of Apramycin

Continuing Medical Education (CME)

CME Programs on Apramycin


Apramycin en Espanol

Apramycin en Francais


Apramycin in the Marketplace

Patents on Apramycin

Experimental / Informatics

List of terms related to Apramycin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Apramycin (also Nebramycin II) is an aminoglycoside antibiotic used in veterinary medicine. It is produced by Streptomyces tenebrarius.[1]



Apramycin is used for the treatment of bacterial infections in animals.

Mechanism of action

Apramycin stands out among aminoglycosides for its mechanism of action which is based on blocking translocation and its ability to bind also to the eukaryotic decoding site despite differences in key residues required for apramycin recognition by the bacterial target. The drug binds in the deep groove of the RNA which forms a continuously stacked helix comprising non-canonical C.A and G.A base pairs and a bulged-out adenine. The binding mode of apramycin at the human decoding-site RNA is distinct from aminoglycoside recognition of the bacterial target, suggesting a molecular basis for the actions of apramycin in eukaryotes and bacteria.

Spectrum of bacterial susceptibility and resistance

Apramycin can be used to treat bacterial infections in animals caused by Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. The following shows susceptibility data on medically significant organisms:

  • Escherichia coli - 1 μg/mL - >512 μg/mL (this large range may be due to resistant organisms, typical MIC values are likely in the range of 2 -8 μg/mL.
  • Klebsiella pneumoniae - 2 μg/mL - >256 μg/mL
  • Pseudomonas aeruginosa - 4 μg/mL



  1. Ryden, R; Moore (1977). "BJ". J Antimicrob Chemother. 3 (6): 609–613. doi:10.1093/jac/3.6.609. PMID 340441.
  2. http://antibiotics.toku-e.com/antimicrobial_1728.html